Background Parkinson's disease (PD) is a progressive multifactorial neurodegenerative
condition. Epidemiological studies have shown that patients with type 2 diabetes mellitus …

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Recent
data highlight similarities between neurodegenerative diseases, including PD and type 2 …

Introduction Accumulating evidence supports the evaluation of glucagon-like peptide-1 (GLP-
1) receptor (R) agonists for the treatment of the underlying pathology causing Parkinson's …

Parkinson's Disease (PD) is a heterogeneous, long-term neurodegenerative condition, for
which there are no therapies proven to slow or stop progression. At the same time …

Introduction Diabetes is a risk factor for Parkinson's disease (PD) and shares similar
dysregulated insulin pathways. Glucagon-like peptide-1 (GLP-1) analogs originally …

The global burden of chronic disorders such as Parkinson's disease (PD) has rapidly
increased over recent decades. Despite an increasing understanding of PD …

Background Parkinson's disease (PD) is a progressive disorder characterised by both motor
and non‐motor problems. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists, licensed for …

Parkinson's disease (PD) is a complex syndrome for which there is no disease-modifying
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …

Highlights•GLP-1 analogs can cross the blood–brain barrier and stimulate the GLP-1
receptor in the brain.•Stimulation of the GLP-1 receptor has shown effects on mitochondrial …

Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon
molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and …